SLC39A7 Antibody

What is SLC39A7 and why is it important in cellular research?

SLC39A7 (also known as ZIP7) is a member of the SLC39 family of zinc transporters that plays a crucial role in maintaining cellular zinc homeostasis. It is the only known SLC39A family member localized on the endoplasmic reticulum membrane and is essential for regulating cytosolic zinc levels . SLC39A7 is particularly important in research because dysregulation has been linked to various diseases, including cancer and neurodegenerative disorders . Its critical function in zinc transport makes it a valuable target for understanding zinc biology and its implications in disease pathology.

What applications are SLC39A7 antibodies typically used for?

SLC39A7 antibodies are validated for multiple research applications:

Most commercially available SLC39A7 antibodies are rabbit polyclonal antibodies with reactivity against human, mouse, and rat SLC39A7 .

What controls should I include when using SLC39A7 antibodies?

For rigorous scientific validation when using SLC39A7 antibodies, include:

• Positive controls: Use cell lines known to express SLC39A7 such as 293T, A-431, LO2, HeLa, mouse heart, mouse pancreas, mouse liver, and rat heart tissues .

• Negative controls: Include isotype controls (rabbit IgG for most SLC39A7 antibodies) to assess non-specific binding.

• Knockdown/knockout validation: SLC39A7 knockdown cells using CRISPR-Cas9 (as demonstrated in several studies) serve as excellent negative controls to confirm antibody specificity .

• Blocking peptide controls: When available, use the specific immunogen peptide to demonstrate binding specificity through signal competition .

How can I effectively use SLC39A7 antibodies to study cellular zinc homeostasis?

To effectively study zinc homeostasis using SLC39A7 antibodies:

• Establish baseline expression: First determine SLC39A7 expression levels in your model system using Western blot with appropriate loading controls (e.g., GAPDH) .

• Combine with zinc imaging: Use SLC39A7 antibodies in immunofluorescence studies alongside zinc-sensitive fluorescent probes to correlate SLC39A7 expression/localization with zinc distribution.

• Zinc manipulation experiments: Design experiments where you:

  • Supplement media with ZnCl₂ and pyrithione (zinc ionophore)

  • Deplete zinc using chelators

  • Then assess SLC39A7 localization and expression changes

• Co-localization studies: Perform double-immunostaining with SLC39A7 antibodies and markers for the endoplasmic reticulum and Golgi apparatus to confirm proper localization.

Research has shown that supplementation with 5 μM ZnCl₂ and 0.5 μM pyrithione can rescue adhesion defects in SLC39A7-knockdown cells, demonstrating the functional relationship between SLC39A7 and zinc transport .

What approaches can resolve contradictory results when using SLC39A7 antibodies in functional studies?

When facing contradictory results with SLC39A7 antibodies:

• Validate antibody specificity: Different SLC39A7 antibodies target different epitopes. For example, some target amino acids 179-224, while others target 235-380 of human SLC39A7 . Confirm which region your antibody targets and consider whether post-translational modifications might affect detection.

• Address clonal variations: Studies have shown that different SLC39A7 knockdown clones (e.g., KD-2 vs. KD-4) may exhibit different phenotypes in cytokine expression and adhesion defects . Always use multiple clones or pools to avoid clone-specific artifacts.

• Cell type considerations: SLC39A7 expression varies across cell types. For instance, cervical cancer cell lines (HeLa, SiHa, CaSki, ME-180) show higher SLC39A7 expression than normal cervical epithelial cells (H8) . Ensure controls are appropriate for your cell type.

• Consider compensatory mechanisms: Research indicates that cells can develop compensatory responses to SLC39A7 knockdown, which may explain result variations. For example, KD-4 cells show greater defects in adhesion and more responsiveness in cytokine production compared to KD-2 cells .

What are the optimal conditions for Western blot detection of SLC39A7?

For optimal Western blot detection of SLC39A7:

If bands appear at unexpected molecular weights, consider that SLC39A7 is a multi-pass membrane protein that may exhibit different migration patterns depending on post-translational modifications or sample preparation methods.

How can I optimize immunofluorescence protocols when using SLC39A7 antibodies?

To optimize immunofluorescence with SLC39A7 antibodies:

• Fixation optimization:

  • For membrane proteins like SLC39A7, test both 4% paraformaldehyde (10-15 min) and methanol/acetone (5-10 min at -20°C)

  • Paraformaldehyde better preserves membrane structure while methanol/acetone improves antibody accessibility

• Permeabilization:

  • Use 0.1-0.2% Triton X-100 for 5-10 minutes

  • For ER/Golgi proteins like SLC39A7, gentler permeabilization with 0.05% saponin may better preserve organelle morphology

• Antibody dilution:

  • Start with 1:50-1:200 for primary antibody based on manufacturer recommendations

  • Incubate overnight at 4°C for best results

• Background reduction:

  • Extend blocking time to 1-2 hours using 5% normal serum from secondary antibody host species

  • Include 0.1% BSA in antibody dilution buffer to reduce non-specific binding

• Co-staining markers:

  • Include ER/Golgi markers (e.g., calnexin, GM130) to confirm expected subcellular localization

  • Use DAPI for nuclear counterstaining

Remember that SLC39A7 localizes primarily to ER and Golgi membranes, so the staining pattern should appear as a perinuclear network rather than plasma membrane or cytoplasmic staining.

How can SLC39A7 antibodies be used to study macrophage function and polarization?

SLC39A7 antibodies are valuable tools for investigating macrophage biology:

• Assessment of polarization markers:

  • Use SLC39A7 antibodies in combination with markers for M1 (NOS2) and M2 (CD206) macrophage phenotypes

  • Studies have shown SLC39A7 knockdown increases CD206 expression while decreasing NOS2, suggesting a role in macrophage polarization

• Phagocytosis assays:

  • After immunostaining with SLC39A7 antibodies, perform phagocytosis assays (e.g., with labeled bacteria)

  • Research demonstrates that SLC39A7-knockdown macrophages show impaired phagocytosis

• Cytokine production analysis:

  • Use SLC39A7 antibodies along with analysis of pro-inflammatory (TNF-α) and anti-inflammatory (IL-10) cytokines

  • Findings indicate SLC39A7 regulates balance between these cytokine responses

• Zinc supplementation experiments:

  • Combine SLC39A7 immunostaining with zinc supplementation (5 μM ZnCl₂ and 0.5 μM pyrithione)

  • This approach can help determine whether observed macrophage defects are zinc-dependent

The established protocol using THP-1 cells stimulated with 100nM PMA provides a reliable model for these studies .

What is the role of SLC39A7 antibodies in cancer research, and how can they be optimally employed?

SLC39A7 antibodies have important applications in cancer research:

• Expression analysis across cancer types:

  • Oncomine data analysis shows SLC39A7 is commonly upregulated in cervical cancer tissues compared to normal controls

  • Compare expression levels across different cancer cell lines versus normal counterparts using Western blot with SLC39A7 antibodies

• Functional studies after gene silencing:

  • Use SLC39A7 antibodies to confirm knockdown efficiency after shRNA or CRISPR-Cas9 targeting

  • Then assess effects on cancer cell phenotypes including:

    • Proliferation (via CCK-8 assay)

    • Apoptosis (via flow cytometry)

    • Migration and invasion (via transwell assays)

• Mechanism investigation:

  • Combine SLC39A7 antibodies with those targeting:

    • Apoptosis regulators (Bax, Bcl-2)

    • Epithelial-mesenchymal transition markers (E-cadherin)

    • Matrix metalloproteinases (MMP-2)

  • Research has shown that SLC39A7 silencing upregulates Bax and E-cadherin while downregulating Bcl-2 and MMP-2

• Tissue microarray analysis:

  • Use SLC39A7 antibodies for IHC on cancer tissue microarrays to correlate expression with clinical outcomes

  • This approach can identify potential prognostic value

These approaches collectively provide insights into SLC39A7's role in cancer progression and its potential as a therapeutic target.

What are the most effective methods for validating SLC39A7 knockdown/knockout when using CRISPR-Cas9 technology?

When validating SLC39A7 knockdown/knockout using CRISPR-Cas9:

• Guide RNA design and selection:

  • Multiple studies have successfully targeted SLC39A7 using gRNAs such as:

    • gRNA2: 5'-CACCGCTCTCCCTCACCAGGCACTG-3'

    • gRNA4: 5'-CACCGAGCTGCTGAGATCAGCACTG-3'

  • Use online CRISPR design tools (e.g., http://crispr.mit.edu/) to identify optimal target sites

• Multi-level validation approach:

  Validation Method	Technical Approach	Expected Outcome
  Protein expression	Western blot with SLC39A7 antibody	Significant reduction/absence of band at ~50 kDa
  mRNA expression	qRT-PCR with SLC39A7-specific primers	Reduced SLC39A7 transcript levels
  Functional validation	Zinc-dependent assays (e.g., proliferation)	Impaired function rescuable with zinc supplementation
  Single-cell isolation	Flow cytometry sorting	Establishment of clonal cell lines
  Genomic validation	Sanger sequencing of target region	Confirmation of indel mutations

• Control considerations:

  • Always include non-target transfected control cells (NC)

  • When possible, generate multiple knockout clones (e.g., KD-2, KD-4) to account for clonal variation

  • Consider rescue experiments by re-expressing SLC39A7 to confirm specificity

• Phenotype assessment:

  • Use CCK-8 proliferation assay, as SLC39A7 knockdown typically reduces proliferation

  • Assess cell adhesion after PMA stimulation, which is often impaired in SLC39A7 knockdown cells

This comprehensive validation ensures the specificity and effectiveness of your CRISPR-Cas9 targeting strategy.

How can cell proliferation assays be optimized when studying the effects of SLC39A7 on zinc-dependent cellular functions?

To optimize cell proliferation assays when studying SLC39A7:

• CCK-8 assay protocol refinement:

  • Seed cells at consistent density (1.5×10⁴ cells/well in 96-well plates)

  • Take measurements at multiple timepoints (24, 48, 72, 96h) to capture proliferation dynamics

  • Include technical triplicates for statistical validity

  • Use phenol red-free media to prevent interference with absorbance readings at 450 nm

• Zinc manipulation experimental design:

  • Include conditions with:

    • Normal media (baseline)

    • Zinc supplementation (5 μM ZnCl₂ with 0.5 μM pyrithione)

    • Zinc chelation (e.g., TPEN at sub-toxic concentrations)

  • This reveals zinc-dependency of observed phenotypes

• Additional complementary assays:

  • Colony formation assays for long-term proliferation assessment

  • EdU incorporation for direct measurement of DNA synthesis

  • Cell cycle analysis by flow cytometry to determine if SLC39A7 affects specific cell cycle phases

• Controls and validation:

  • Include both SLC39A7 knockdown and overexpression conditions

  • Assess SLC39A7 expression levels by Western blot in parallel

  • Determine cell viability (e.g., SYTOX Green staining) to distinguish between proliferation and survival effects